Drug Approval | February 21, 2023
Astellas updates on Fezolinetant application in US
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
There is a fast resurgence in the transplant activities post COVID
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC
The workshop strived to sensitize states and various stakeholder departments regarding their role in the implementation of National Patient Safety Implementation Framework, as well as augment capacity building of health care professionals
eSanjeevani 2.0 will enhance the telemedicine experience further with a plethora of new features both in terms of technology as well as innovation
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
Subscribe To Our Newsletter & Stay Updated
